


MGP-104US

PATENT

1653

P#5



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kamel F. Egbaria et al. : Art Unit: 1653
Serial No.: 09/943,687 : Examiner:
Filed: August 31, 2001 :
For: SPONTANEOUS EMULSIONS :
CONTAINING CYCLOSPORINE :

RECEIVED

APR 09 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R :

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO 1449 (R&P) submitted herewith. A copy of each of the listed references is also enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

More than three months have elapsed since the filing of the above-referenced application. No first Official Action has yet been received and it is presumed that none has yet been mailed. No fee or certification is required. 37 C.F.R. § 1.97(b).

Respectfully submitted,



Christopher R. Lewis, Reg. No. 36,201
Attorney for Applicant

Enclosures: USPTO Form 1449
Copy of three (3) references


Dated: March 18, 2002

P.O. Box 980
Valley Forge, PA 19482-0980
(610) 407-0700

The Assistant Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. **18-0350** of any fees associated with this communication.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on:

March 18, 2002



Christopher R. Lewis

FORM PTO-1449
(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

MGP-104US

SERIAL NO

09/943.687

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

APPLICANT

Kamel F. Egbaria et al.

FILING DATE

August 31, 2001

GROUP

1653

U.S. PATENT DOCUMENTS

RECEIVED

APR 09 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, Etc.)

InitialDocument
Number

Date _____

Country

Class:

Sub
Class

Translation
YES | NO

(Including Author, Title, Date, Pertinent Pages, Etc.)

1)

Craig et al., "An investigation into the effects of drug inclusion on the dielectric response, surface tension and droplet size distribution of self-emulsifying systems," *International Journal of Pharmaceutics*, 96:147-155, 1993.

2)

Shah et al., "Self-emulsifying drug delivery system (SEDDS) with polyglycolized glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs," *International Journal of Pharmaceutics*, 106:15-23, 1996.

3)

Charman, et al., "Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound, *Pharmaceutical Research*, Vol. 9, No. 1, 1992.

Examiner

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.